Cargando…

Developments in the treatment of Fabry disease

Enzyme replacement therapy (ERT) with recombinant α‐galactosidase A (r‐αGAL A) for the treatment of Fabry disease has been available for over 15 years. Long‐term treatment may slow down disease progression, but cardiac, renal, and cerebral complications still develop in most patients. In addition, l...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Veen, Sanne J., Hollak, Carla E. M., van Kuilenburg, André B. P., Langeveld, Mirjam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540041/ https://www.ncbi.nlm.nih.gov/pubmed/32083331 http://dx.doi.org/10.1002/jimd.12228

Ejemplares similares

Predicting the Development of Anti-Drug Antibodies against Recombinant alpha-Galactosidase A in Male Patients with Classical Fabry Disease
por: van der Veen, Sanne J., et al.
Publicado: (2020)

Antibodies against recombinant enzyme in the treatment of Fabry disease: Now you see them, now you don’t
por: van der Veen, Sanne Jolien, et al.
Publicado: (2022)

Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation
por: van Kuilenburg, André B. P., et al.
Publicado: (2023)

Influence of sex and phenotype on cardiac outcomes in patients with Fabry disease
por: El Sayed, Mohamed, et al.
Publicado: (2021)

The Mini Mental State Examination does not accurately screen for objective cognitive impairment in Fabry Disease
por: Körver, Simon, et al.
Publicado: (2019)

Cognitive functioning and depressive symptoms in Fabry disease: A follow‐up study
por: Körver, Simon, et al.
Publicado: (2020)

Depressive symptoms in Fabry disease: the importance of coping, subjective health perception and pain
por: Körver, Simon, et al.
Publicado: (2020)

Predictors of objective cognitive impairment and subjective cognitive complaints in patients with Fabry disease
por: Körver, Simon, et al.
Publicado: (2019)

Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors
por: Arends, Maarten, et al.
Publicado: (2017)

Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study
por: Arends, Maarten, et al.
Publicado: (2018)

Quality of life in patients with Fabry disease: a systematic review of the literature
por: Arends, Maarten, et al.
Publicado: (2015)

ECG Changes during Adult Life in Fabry Disease: Results from a Large Longitudinal Cohort Study
por: El Sayed, Mohamed, et al.
Publicado: (2023)

Cost-effectiveness of enzyme replacement therapy for Fabry disease
por: Rombach, Saskia M, et al.
Publicado: (2013)

Poikilothermia in a 38-year-old Fabry patient
por: Biegstraaten, Marieke, et al.
Publicado: (2010)

Renal involvement in a patient with the chronic visceral subtype of acid sphingomyelinase deficiency resembles Fabry disease
por: Eskes, Eline C. B., et al.
Publicado: (2021)

Pain management strategies for neuropathic pain in Fabry disease - a systematic review
por: Schuller, Y., et al.
Publicado: (2016)

Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease
por: Shu, Liming, et al.
Publicado: (2014)

Erratum to: Pain management strategies for neuropathic pain in Fabry disease - a systematic review
por: Schuller, Y., et al.
Publicado: (2016)

Autonomic neuropathy in Fabry disease: a prospective study using the Autonomic Symptom Profile and cardiovascular autonomic function tests
por: Biegstraaten, Marieke, et al.
Publicado: (2010)

Prevalence of symptoms in female Fabry disease patients: a case-control survey
por: Bouwman, Machtelt G., et al.
Publicado: (2012)

Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain
por: Rombach, Saskia M, et al.
Publicado: (2013)

Fabry disease
por: Germain, Dominique P
Publicado: (2010)

Registries for orphan drugs: generating evidence or marketing tools?
por: Hollak, Carla E. M., et al.
Publicado: (2020)

Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study
por: Arends, Maarten, et al.
Publicado: (2017)

Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy
por: Morrissey, Ryan P, et al.
Publicado: (2011)

Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg
por: Vedder, Anouk C., et al.
Publicado: (2007)

Recurrent metabolic alkalosis following ketone body treatment of adult mitochondrial trifunctional protein deficiency: A case report
por: Stolwijk, Nina N., et al.
Publicado: (2022)

An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease
por: Hollak, Carla EM
Publicado: (2012)

Bone health in patients with inborn errors of metabolism
por: Langeveld, M., et al.
Publicado: (2018)

Fabry Disease: The Current Treatment Landscape
por: Lenders, Malte, et al.
Publicado: (2021)

Treatment of Fabry Disease: Established and Emerging Therapies
por: Umer, Muhammad, et al.
Publicado: (2023)

Patients’ view on gene therapy development for lysosomal storage disorders: a qualitative study
por: Eskes, Eline C. B., et al.
Publicado: (2022)

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
por: Biegstraaten, Marieke, et al.
Publicado: (2015)

Agalsidase alfa (Replagal(™)) in the treatment of Anderson-Fabry disease
por: Pastores, Gregory M
Publicado: (2007)

Anderson-Fabry disease in heart failure
por: Akhtar, M. M., et al.
Publicado: (2018)

Ophthalmic Manifestations in Fabry Disease: Updated Review
por: Gambini, Gloria, et al.
Publicado: (2023)

Fabry Disease – Current Treatment and New Drug Development
por: Motabar, Omid, et al.
Publicado: (2010)

Biomarkers in Anderson–Fabry Disease
por: Simonetta, Irene, et al.
Publicado: (2020)

Hot topics in Fabry disease
por: Cairns, Tereza, et al.
Publicado: (2018)

Chaperone Therapy in Fabry Disease
por: Weidemann, Frank, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vsfejejun97m0oea2e2hr2k57o